HealthEquity Inc. (HQY)
Here's Why HealthEquity (HQY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Add HealthEquity Stock to Your Portfolio for Now
HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q2 results, though data security threats remain a key risk.
HealthEquity Rolls Out Agentic AI to Elevate Member Support Experience
HQY's new agentic AI is likely to provide faster, more intuitive support across channels, aiming to boost member satisfaction.
Final Trades: Taiwan Semi, HealthEquity, CBOE Global Markets and the XBI
The Investment Committee give you their top stocks to watch for the second half.
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HQY Expands Access With GLP-1 Telehealth & Direct HSA Platforms
HealthEquity rolls out GLP-1 telehealth and direct HSA enrollment platforms, targeting affordability and growth amid rising healthcare costs and regulatory expansion.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HealthEquity: Swing Trading Stock With A Beat And Raise
HealthEquity reported strong Q2 results with revenue and earnings beats, but valuation remains stretched, justifying a neutral-to-cautiously bullish rating. The company operates in a large, growing healthcare savings market, with solid account and asset growth driven mostly by organic expansion. Financial metrics were robust: revenue up 8.6%, adjusted EBITDA up 18%, and margin expansion, with continued share repurchases but no dividend yet.
HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y
HQY's Q2 results reflect EPS growth of 25.6% year over year, revenue growth of 8.6% and a 12% increase in HSA. The company also updates its fiscal 2026 guidance.
HealthEquity: Scale Platform With Asset‑Linked Revenues And Thick Incremental Margins
HQY remains a buy for long-term investors, with exceptional economics, high margins, and capital-light growth despite recent multiple contraction. Q1 FY26 results showed strong revenue and earnings growth, margin expansion, and operating leverage, confirming the business is scaling efficiently. The recurring, asset-linked revenue model benefits from secular healthcare tailwinds, high switching costs, and robust cash conversion cycles.
Countdown to HealthEquity (HQY) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Get a deeper insight into the potential performance of HealthEquity (HQY) for the quarter ended July 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY's HSA growth, AI-driven efficiencies, and strong Q1 results fuel optimism despite data security concerns.
